A clinical study to evaluate the efficacy and safety of Fumaderm® in young patients aged 10 to 17 years with moderate to severe psoriasis vulgaris (KIFUderm study).

Registry ID

EUCTR2012-000035-82

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Biogen GmbH

Start date

2012-10-22

Completion date

2016-09-20

Last update

2026-08-16

Conditions

• Psoriasis vulgaris

Summary

The primary objective is to evaluate the efficacy and safety of Fumaderm® in patients with moderate to severe psoriasis compared to placebo as assessed by the primary endpoints PASI 75 and/ or PGA 0 or 1 (clear or almost clear) during a 20 week treatment phase.

Locations

• , , Germany

Related clinical trials

• Investigation of maintaining factors of depressive disorders in patients with psoriasis
• Evaluation of a structured, guideline-based, multimodal care model for people with inflammatory skin diseases
• Pharmacological conditioning as a drug dose reduction strategy in patients with psoriasis
• Characterising inflammatory and malignant skin diseases
• Pruritus and Psoriasis - experimental analyses of itch in patients with psoriasis
• Disease trajectories in Atopic Dermatitis and Psoriasis

View on source registry